Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron
Will the first Covid-19 pill be all that useful? How worrisome is Omicron? And when will it be safe to congregate?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Matthew Herper joins us to talk about a tense debate among FDA advisers about molnupiravir, a Merck treatment for Covid-19 whose luster has faded over time. Then, we talk to Emory University’s Carlos del Rio about the potential of Pfizer’s antiviral pill, the future treatment landscape for Covid-19, and how the emerging Omicron variant might change the global pandemic response.
Read Original Article: Carlos del Rio on Covid antivirals, an FDA conundrum, & the rise of Omicron »
